Ken Griffin Galectin Therapeutics Inc Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $5,751 - $11,340	2,700 New	2,700 $6,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $7,040 - $9,592	4,400 New	4,400 $7,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $1,188 - $1,872	-900 Reduced 27.27%	2,400 $3,000
Q1 2023 May 15, 2023	SELL	$1.1 - $2.4 $1,320 - $2,880	-1,200 Reduced 26.67%	3,300 $6,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $4,635 - $7,470	4,500 New	4,500 $5,000

9.35M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $169M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.